Vincent Chung, M.D.

(877) 460-4673
Vincent Chung, M.D.
Medical Oncologist
Clinical Expertise
  • Pancreatic Cancer
  • Gastrointestinal Cancers
  • Phase 1/Early Therapeutics
Research Area
  • Gastrointestinal Cancer
Academic Appointments
  • Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Bile Duct Cancer
Colorectal Cancer
Esophageal Cancer
Gallbladder Cancer
Gastrointestinal Cancers
Gastrointestinal Carcinoid Tumors
Hereditary Colorectal Cancer Multidisciplinary Program
Liver Cancers and Liver Tumors
Medical Oncology & Therapeutics Research
Pancreatic Cancer
Small Intestine Cancer
Stomach (Gastric) Cancer
Research Teams
Developmental Cancer Therapeutics Program (CCC)
Vincent Chung, M.D., is a medical oncologist specializing in pancreatic cancer and gastrointestinal cancers. A member of the City of Hope team since 2002, Dr. Chung, was voted one of “America's Top Doctors” by Castle Connolly in 2013.
 
Dr. Chung leads a long list of clinical trials examining new drugs to treat advanced solids tumors and immunotherapy options for inoperable pancreatic cancer.
 
Dr. Chung received his medical degree from the University of Tennessee at Memphis, and was chief resident at California Pacific Medical Center in San Francisco.

Location

Education & Experience

Board Certifications

  • 2005, Diplomate, American Board of Oncology

  • 2001, Diplomate, American Board of Internal Medicine

Degrees

  • 1994-1998, M.D., Medicine, University of Tennessee at Memphis, Memphis, TN

  • 1990-1993, B.A., Molecular and Cell Biology/Biochemistry, University of California Berkeley, Berkeley, CA

Fellowship

  • 2002-2005, City of Hope, Duarte, CA

Residency

  • 2001-2002, Chief Resident, Medicine, California Pacific Medical Center, San Francisco, CA

  • 1999-2001, Resident, Medicine, California Pacific Medical Center, San Francisco, CA

Internship

  • 1998-1999, Intern, Medicine, California Pacific Medical Center, San Francisco, CA

Professional Experience

  • 2020-present, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA

  • 2005-2020, Associate Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA

  • 2004-2005, Fellow, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2002-2004, Fellow, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA

Awards & Memberships

Memberships

  • 2005-present, American Association of Cancer Research

  • 2004-present, American Society of Clinical Oncology

  • 2004-present, American Society of Hematology

  • 1999-2003, American College of Physicians, American Society of Internal Medicine

Publications

  • Connolly RM, Laille E, Vaishampayan U, Chung V, Kelly K, Dowlati A, Alese OB, Harvey RD, Haluska P, Siu LL, Kummar S, Piekarz R, Ivy SP, Anders NM, Downs M, O'Connor A, Scardina A, Saunders J, Rosner GL, Carducci MA, Rudek MA. ETCTN-9008 Study Team. Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. Clin Cancer Res. 2020 Oct 15;26(20):5329-5337. doi: 10.1158/1078-0432.CCR-20-1412. Epub 2020 Aug 14.PMID: 32816943
  • Pooler DB, Ness DB, Sarantopoulos J, Squittieri N, Ravichandran S, Britten CD, Amaravadi RK, Vaishampayan U, LoRusso P, Shapiro GI, Olszanski AJ, Perez R, Gutierrez M, O'Rourke MA, Chung V, Lee JJ, Lewis LD. The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. Br J Clin Pharmacol. 2020 Jul 31. doi: 10.1111/bcp.14508. Online ahead of print. PMID: 32736411
  • Frankel PH, Chung V, Xing Y, Longmate J, Groshen S, Newman EM. Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology. Curr Probl Cancer. 2020 May 7:100583. doi: 10.1016/j.currproblcancer.2020.100583. Online ahead of print. PMID: 32446637
  • Frankel PH, Chung V, Tuscano J, Siddiqi T, Sampath S, Longmate J, Groshen S, Newman EM. Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies. JAMA Netw Open. 2020 May; 3(5): e204787. PMCID: PMC7221509 doi:10.1001/jamanetworkopen.2020.4787 PMID: 32401317
  • Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol. 2020 Apr 30;6(6):1-8. doi: 10.1001/jamaoncol.2020.0930. Online ahead of print.PMID: 32352498
  • Ferrell B, Chung V, Koczywas M, Borneman T, Irish TL, Ruel NH, Azad NS, Cooper RS, Smith TJ. Spirituality in cancer patients on phase 1 clinical trials. Psychooncology. 2020 Mar 29. doi: 10.1002/pon.5380. [Epub ahead of print] PMID: 32227382
  • Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, Mikhail S, Chung V, Sahai V, Sohal DPS, Bellakbira S, Thach D, Rahib L, Madhavan S, Matrisian LM, Petricoin EF 3rd. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020 Apr;21(4):508-518. doi: 10.1016/S1470-2045(20)30074-7. Epub 2020 Mar 2. Erratum in: Lancet Oncol. 2020 Apr;21(4):e182. PMID: 32135080
  • Ferrell BR, Chung V, Koczywas M, Smith TJ. Dissemination and Implementation of Palliative Care in Oncology. J Clin Oncol. 2020 Mar 20;38(9):995-1001. doi: 10.1200/JCO.18.01766. Epub 2020 Feb 5. PMID: 32023151; PMCID: PMC7082157.
  • Chung V, Kos FJ, Hardwick N, Yuan Y, Chao J, Li D, Waisman J, Li M, Zurcher K, Frankel P, Diamond DJ. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. Clin Transl Oncol. 2019 Mar;21(3):363-372. doi: 10.1007/s12094-018-1932-2. Epub 2018 Aug 9.
  • Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, Johnson F, Kovach JS. Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. Clin Cancer Res. 2017 Jul 1;23(13):3277-3284. doi: 10.1158/1078-0432.CCR-16-2299. PMID: 28039265 DOI: 10.1158/1078-0432.CCR-16-2299
  • Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol. 2017 Apr 1;3(4):516-522. doi: 10.1001/jamaoncol.2016.5383. PMID: 27978579 PMCID: PMC5665683 DOI: 10.1001/jamaoncol.2016.5383
  • Chung V, Frankel P, Lim D, Yeon C, Leong L, Chao J, Ruel N, Luevanos E, Koehler S, Chung S, Lau SC, Fakih MG. Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. Oncology. 2016 Apr 20. [Epub ahead of print] PMID: 27093189
  • Chung V, Heath EI, Schelman WR, Johnson BM, Kirby LC, Lynch KM, Botbyl JD, Lampkin TA, Holen KD. First-Time-In-Human Study of GSK923295, a Novel Anti-Mitotic Inhibitor of Centromere-Associated Protein E (CENP-E), in Patients with Refractory Cancer Chemother Pharmacol. 69 (3): 733-741, 2011. PMID: 22020315
  • Chung V, Zhou B, Liu X, Boo LM, Nguyen HV, Ann DK, Song J, Chen Y, Yen Y. SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone. Mol Cancer Ther. 2006 Mar;5(3):533-40.  PMID: 16546967

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Show respect for what you say
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Know important info medical history
4.8
Recommend this provider office
4.8
Spend enough time with you
4.8
Rate provider 0-10
01/14/25
Excellent doctor in all domains - Verified patient
01/14/25
Invaluable - Verified patient
12/27/24
Doctor seems to be in a hurry most of the time, don't get to seen him often [...] Doctor is a genius and would never change him but needs to slow down in my visit. My brain has slowed down and can't keep up with him sometimes but will always answer portal. I love you all. - Verified patient
12/13/24
Dr Chung was congenial, clear, and efficient in his communications. - Verified patient
11/09/24
Everyone communicates with me and each other - Verified patient